Bimagrumab for sporadic inclusion body myositis – first line
Sporadic inclusion body myositis is a rare disease that affects the muscles of older people. It causes weakness and can lead to difficulties standing and walking safely without falling. There is currently no treatment for this disease.
Bimagrumab is a new drug being developed for sporadic inclusion myositis. It is given straight into the blood stream through a drip once every 4 weeks. A study is currently running to see how well it works to improve patients’ walking abilities and to see if it is safe to use.
If it is licensed for use in the UK, bimagrumab will be the first treatment available for people with sporadic inclusion body myositis.